FDA Announces Joint Meeting of Psychopharmacologic Drugs and Drug Safety Advisory Committees

Summary

The US Food and Drug Administration (FDA) is hosting a joint meeting of its Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, where the public can provide input on regulatory issues, and the FDA is seeking public comments on the meeting and its agenda.